乳腺癌化疗进展-PPT精选课件.ppt

1、张忠清张忠清 乳腺癌当前流行趋势分析乳腺癌当前流行趋势分析 中国肿瘤中国肿瘤 2000 9 2000 9（1010）：）：454454张忠清张忠清 乳腺癌当前流行趋势分析乳腺癌当前流行趋势分析 中国肿瘤中国肿瘤 2000 9 2000 9（1010）：）：454454张忠清张忠清 乳腺癌当前流行趋势分析乳腺癌当前流行趋势分析 中国肿瘤中国肿瘤 2000 9 2000 9（1010）：）：454454 Dr.Ann Thor Dr.Ann ThorThe 2nd International Breast Cancer International Research Group Conference

2、The 2nd International Breast Cancer International Research Group Conference Dr.Ann Thor Dr.Ann ThorThe 2nd International Breast Cancer International Research Group ConferenceThe 2nd International Breast Cancer International Research Group Conference Dr.Ann Thor Dr.Ann ThorThe 2nd International Breas

3、t Cancer International Research Group ConferenceThe 2nd International Breast Cancer International Research Group Conference 江泽飞江泽飞 紫杉类药物在乳腺癌化疗中的地位和临床研究进展紫杉类药物在乳腺癌化疗中的地位和临床研究进展 中国医学论坛报网络版中国医学论坛报网络版866866期期江泽飞江泽飞 紫杉类药物在乳腺癌化疗中的地位和临床研究进展紫杉类药物在乳腺癌化疗中的地位和临床研究进展 中国医学论坛报网络版中国医学论坛报网络版866866期期Bishop JF.Initia

4、l paclitaxel improves outcome compared Bishop JF.Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.in untreated metastatic breast cancer.J Clin Oncol.201

5、9 Aug;17(8):2355J Clin Oncol.2019 Aug;17(8):2355Bishop JF.Initial paclitaxel improves outcome compared Bishop JF.Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy with CMFP combination chemotherapy as front-line therapy in untreated metastatic brea

6、st cancer.in untreated metastatic breast cancer.J Clin Oncol.2019 Aug;17(8):2355J Clin Oncol.2019 Aug;17(8):2355Bishop JF.Initial paclitaxel improves outcome compared Bishop JF.Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy with CMFP combination

7、 chemotherapy as front-line therapy in untreated metastatic breast cancer.in untreated metastatic breast cancer.J Clin Oncol.2019 Aug;17(8):2355J Clin Oncol.2019 Aug;17(8):2355Bishop JF.Initial paclitaxel improves outcome compared Bishop JF.Initial paclitaxel improves outcome compared with CMFP comb

8、ination chemotherapy as front-line therapy with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.in untreated metastatic breast cancer.J Clin Oncol.2019 Aug;17(8):2355J Clin Oncol.2019 Aug;17(8):2355Bishop JF.Initial paclitaxel improves outcome compared Bisho

9、p JF.Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.in untreated metastatic breast cancer.J Clin Oncol.2019 Aug;17(8):2355J Clin Oncol.2019 Aug;17(8):

10、2355Bishop JF.Initial paclitaxel improves outcome compared Bishop JF.Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.in untreated metastatic breast can

11、cer.J Clin Oncol.2019 Aug;17(8):2355J Clin Oncol.2019 Aug;17(8):2355StocklerStocklerThe 2nd International Breast CancerInternational Research Group ConferenceThe 2nd International Breast CancerInternational Research Group ConferenceSledge GW.Phase III trial of doxorubicin,paclitaxel,and the combinat

12、ion Sledge GW.Phase III trial of doxorubicin,paclitaxel,and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer:an intergroup trial(E1193).cancer:an intergroup trial(E1193

13、).J Clin Oncol.2019 Feb 15;21(4):588J Clin Oncol.2019 Feb 15;21(4):588 Sledge GW.Phase III trial of doxorubicin,paclitaxel,and the combination Sledge GW.Phase III trial of doxorubicin,paclitaxel,and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast of dox

14、orubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer:an intergroup trial(E1193).cancer:an intergroup trial(E1193).J Clin Oncol.2019 Feb 15;21(4):588J Clin Oncol.2019 Feb 15;21(4):588 0%0%5%5%10%10%15%15%20%20%25%25%30%30%35%35%40%40%45%45%50%50%A AT TA+TA+TCR+PRCR+PRSledge

15、 GW.Phase III trial of doxorubicin,paclitaxel,and the combination Sledge GW.Phase III trial of doxorubicin,paclitaxel,and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast canc

16、er:an intergroup trial(E1193).cancer:an intergroup trial(E1193).J Clin Oncol.2019 Feb 15;21(4):588J Clin Oncol.2019 Feb 15;21(4):588 0 01 12 23 34 45 56 67 78 8A AT TA+TA+TTTF(月)TTF(月)Sledge GW.Phase III trial of doxorubicin,paclitaxel,and the combination Sledge GW.Phase III trial of doxorubicin,pac

17、litaxel,and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer:an intergroup trial(E1193).cancer:an intergroup trial(E1193).J Clin Oncol.2019 Feb 15;21(4):588J Clin Oncol

18、.2019 Feb 15;21(4):588 171717.517.5181818.518.5191919.519.5202020.520.5212121.521.5222222.522.5A AT TA+TA+TMS(月)MS(月)Sledge GW.Phase III trial of doxorubicin,paclitaxel,and the combination Sledge GW.Phase III trial of doxorubicin,paclitaxel,and the combination of doxorubicin and paclitaxel as front-

19、line chemotherapy for metastatic breast of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer:an intergroup trial(E1193).cancer:an intergroup trial(E1193).J Clin Oncol.2019 Feb 15;21(4):588J Clin Oncol.2019 Feb 15;21(4):588 Sledge GW.Phase III trial of doxorubicin,pac

20、litaxel,and the combination Sledge GW.Phase III trial of doxorubicin,paclitaxel,and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer:an intergroup trial(E1193).cancer:a

21、n intergroup trial(E1193).J Clin Oncol.2019 Feb 15;21(4):588J Clin Oncol.2019 Feb 15;21(4):588 Sledge GW.Phase III trial of doxorubicin,paclitaxel,and the combination Sledge GW.Phase III trial of doxorubicin,paclitaxel,and the combination of doxorubicin and paclitaxel as front-line chemotherapy for

22、metastatic breast of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer:an intergroup trial(E1193).cancer:an intergroup trial(E1193).J Clin Oncol.2019 Feb 15;21(4):588J Clin Oncol.2019 Feb 15;21(4):588 Dr.George SledgeDr.George SledgeThe 2nd International Breast Cance

23、rInternational Research Group ConferenceThe 2nd International Breast CancerInternational Research Group ConferenceDr.George SledgeDr.George SledgeThe 2nd International Breast CancerInternational Research Group ConferenceThe 2nd International Breast CancerInternational Research Group ConferenceChan S

24、.Prospective randomized trial of docetaxel Chan S.Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast versus doxorubicin in patients with metastatic breast cancer.The 303 Study Group.cancer.The 303 Study Group.J Clin Oncol.2019 Aug;17(8):2341 J Clin Oncol.

25、2019 Aug;17(8):2341 Chan S.Prospective randomized trial of docetaxel Chan S.Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast versus doxorubicin in patients with metastatic breast cancer.The 303 Study Group.cancer.The 303 Study Group.J Clin Oncol.2019 Au

26、g;17(8):2341 J Clin Oncol.2019 Aug;17(8):2341 Chan S.Prospective randomized trial of docetaxel Chan S.Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast versus doxorubicin in patients with metastatic breast cancer.The 303 Study Group.cancer.The 303 Study

27、Group.J Clin Oncol.2019 Aug;17(8):2341 J Clin Oncol.2019 Aug;17(8):2341 Nabholtz JM.Prospective randomized trial of docetaxel versus mitomycin plusNabholtz JM.Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite vin

28、blastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy.304 Study Group.previous anthracycline-containing chemotherapy.304 Study Group.J Clin Oncol.2019 May;17(5):1413-24 J Clin Oncol.2019 May;17(5):1413-24 Nabholtz JM.Prospective randomi

29、zed trial of docetaxel versus mitomycin plusNabholtz JM.Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containin

30、g chemotherapy.304 Study Group.previous anthracycline-containing chemotherapy.304 Study Group.J Clin Oncol.2019 May;17(5):1413-24 J Clin Oncol.2019 May;17(5):1413-24 0.00%0.00%5.00%5.00%10.00%10.00%15.00%15.00%20.00%20.00%25.00%25.00%30.00%30.00%35.00%35.00%多西紫杉醇多西紫杉醇MVMV总有效率总有效率内脏转移内脏转移肝转移肝转移蒽环类耐药蒽

31、环类耐药Nabholtz JM.Prospective randomized trial of docetaxel versus mitomycin plusNabholtz JM.Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite vinblastine in patients with metastatic breast cancer progressing despi

32、te previous anthracycline-containing chemotherapy.304 Study Group.previous anthracycline-containing chemotherapy.304 Study Group.J Clin Oncol.2019 May;17(5):1413-24 J Clin Oncol.2019 May;17(5):1413-24 Nabholtz JM.Prospective randomized trial of docetaxel versus mitomycin plusNabholtz JM.Prospective

33、randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy.304 Study Group.previous anthracycline-containing che

34、motherapy.304 Study Group.J Clin Oncol.2019 May;17(5):1413-24 J Clin Oncol.2019 May;17(5):1413-24 Nabholtz JM.Prospective randomized trial of docetaxel versus mitomycin plusNabholtz JM.Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast canc

35、er progressing despite vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy.304 Study Group.previous anthracycline-containing chemotherapy.304 Study Group.J Clin Oncol.2019 May;17(5):1413-24 J Clin Oncol.2019 May;17(5):1413-24 Dr.Na

36、bholtzDr.NabholtzThe 2nd International Breast CancerInternational Research Group ConferenceThe 2nd International Breast CancerInternational Research Group ConferenceDr.NabholtzDr.NabholtzThe 2nd International Breast CancerInternational Research Group ConferenceThe 2nd International Breast CancerInte

37、rnational Research Group ConferenceDr.BurrisDr.BurrisThe 2nd International Breast CancerInternational Research Group ConferenceThe 2nd International Breast CancerInternational Research Group ConferenceA,doxorubicin;C,cyclophosphamide;D,docetaxel;F,5-fluorouracil;P,paclitaxel;DFS,disease-free survival;NS,not significant.P values based upon Cox model.江泽飞江泽飞 紫杉类药物在乳腺癌化疗中的地位和临床研究进展紫杉类药物在乳腺癌化疗中的地位和临床研究进展 中国医学论坛报网络版中国医学论坛报网络版866866期期